PRESS-RELEASE ·Filed Apr 27, 2026
Press release · FDA
Actionable Insight • Neutral
No immediate trading catalyst. Monitor actual data presentations at ADA in June 2026 for potential stock-moving results.
GPCR drugs
GPCR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60Entry
$43.56
T+0 close · Apr 27, 2026 · via day close
Latest settled
+16.62%
T+60 · $50.80
Vs SPY
+12.63%
α at T+60
Horizons
All settled
through T+60
- T+0 · Apr 28 $43.56entry
- T+1 · 7mo ago −4.26%α −4.25% · $41.71
- T+5 · 7mo ago −1.19%α −2.89% · $43.04
- T+20 · 6mo ago −9.14%α −14.60% · $39.58
- T+60 · 4mo ago +16.62%α +12.63% · $50.80
Price Chart
REPLAYWatch the reaction play outLoading chart...
How similar events traded
Executive Summary
Structure Therapeutics announced multiple presentations at the ADA 86th Scientific Sessions, including an oral presentation of Phase 2b ACCESS trial data for aleniglipron. No clinical results were disclosed in this press release.
Key Facts
- Five presentations at ADA 2026 including oral on ACCESS Phase 2b trial of aleniglipron
- Combination therapy data with oral GLP-1 and amylin receptor agonists in NHPs
- Lower starting dose data to improve GI tolerability
- No clinical efficacy or safety data released in this announcement
Financial Impact
No financial impact from this press release alone.
Risk Factors
- Clinical trial failure risk for aleniglipron
- Intense competition from injectable GLP-1 drugs (semaglutide, tirzepatide)
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282005 |
Track record
10 reports on GPCR
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $21.73 Now $18.57 −14.54% settles Feb 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $19.08 Now $18.57 −2.67% settles Feb 3
- Jun 11, 202622w ago Institutional Cluster Bearish 5/10 Entry $43.30 to $47.34 Now $18.57 +57.11% ▼ −9.33% −4.93% vs SPY
- May 7, 202627w ago 8-K Mixed 6/10 Entry $39.10 to $49.64 Now $18.57 −52.51% ▲ +26.96% +22.12% vs SPY
- Apr 27, 202629w ago Press Release Neutral 2/10 Viewing Entry $43.56 to $50.80 Now $18.57 −57.37% ▲ +16.62% +12.63% vs SPY
- Apr 15, 202630w ago 8-K Neutral 3/10 Entry $54.25 to $53.36 Now $18.57 −65.77% ▼ −1.64% −9.78% vs SPY
- Mar 16, 202635w ago Press Release Bullish 8/10 Entry $56.65 to $37.77 Now $18.57 −67.22% ▼ −33.33% −43.81% vs SPY
- Feb 28, 202637w ago Institutional Cluster Mixed 6/10 Entry $62.90 to $39.58 Now $18.57 −70.48% ▼ −37.07% −46.40% vs SPY
Showing 10 of 10
US Market Status
Market Closed · Opens Wed (11h 30m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers